3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
31
Lymphoma
19
Neoplasms, Plasma Cell
16
Myelodysplastic Syndromes
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, Non-Hodgkin
13
Leukemia, Myeloid, Acute
13
Leukemia
13
Hodgkin Disease
12
Leukemia, Lymphocytic, Chronic, B-Cell
9
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
7
Retinoblastoma
6
Lymphoma, Mantle-Cell
6
Burkitt Lymphoma
6
Myeloproliferative Disorders
5
Immunoglobulin Light-chain Amyloidosis
5
Recurrence
4
Primary Myelofibrosis
4
Ovarian Neoplasms
4
Neuroblastoma
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myelomonocytic, Juvenile
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hematologic Neoplasms
4
Congenital Abnormalities
4
Sezary Syndrome
3
Myelodysplastic-Myeloproliferative Diseases
3
Interventions
Rituximab
4
Etoposide
3
cobomarsen
2
Vincristine
2
Prednisone
2
Ifosfamide
2
Doxorubicin
2
Cyclophosphamide
2
Carboplatin
2
ponatinib
1
ibritumomab tiuxetan
1
dacetuzumab
1
Vorinostat
1
Melphalan
1
Imatinib Mesylate
1
Cytarabine
1
Carmustine
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Immunoproliferative Disorders
×
Melphalan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts